IQVIA Holdings stock fell 0.86 percent before Q3 results
IQVIA Holdings stock declined 0.86% ahead of its Q3 earnings report, following strong Q2 results where adjusted EPS and revenue surpassed expectations. Analysts have set a modest average price target of USD 264.31, suggesting limited upside from the current price. Investors are watching to see if the company can maintain its growth trajectory and booking trends, particularly given its net debt and leverage.
IQVIA Holdings schedules results. IQVIA Holdings stock trades at EUR 229.45
IQVIA Holdings (US46266C1053) stock was trading at EUR 229.45 in weekend trading on October 3, 2026, matching its last Xetra close. The company announced it would report its third-quarter 2026 financial results on October 27, 2026, before market open. Additionally, IQVIA Inc., a wholly-owned subsidiary, recently priced USD 2 billion in senior notes due 2034 to redeem existing notes and repay part of its credit facility.
IQVIA Holdings Inc. (IQV) stock price, news, quote and history - Yahoo Finance
This Yahoo Finance page provides a comprehensive overview of IQVIA Holdings Inc. (IQV) stock, including its current price, recent news headlines, and historical performance data. It highlights that the stock closed at $258.21, with various news articles discussing its valuation, recent gains, and strategic moves like pricing $2 billion in notes. The performance overview shows that IQVIA has outperformed the S&P 500 year-to-date and over the past year.
UBS upgrades IQVIA stock to Strong Buy rating
UBS Group has upgraded IQVIA Holdings (ISIN US46266C1053) stock to a Strong Buy rating. This upgrade comes as IQVIA reported strong second-quarter 2026 results, with adjusted earnings per share and revenue exceeding consensus estimates, driven by healthy industry demand and improving biotech activity. Despite a slight daily decline in its EUR quote, the company's strong bookings growth, cash generation, and higher analyst targets provide a positive outlook.
Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity
IQVIA Holdings reported strong Q2 2026 results, with adjusted earnings and revenues surpassing Zacks Consensus Estimates. The company leverages its extensive data, AI-driven capabilities, and solid bookings in R&D Solutions, while also engaging in share repurchases. Despite its strong performance, IQVIA has low liquidity and does not plan to issue cash dividends due to its financial condition and debt.
IQVIA Holdings Inc. (IQV) Options Chain
This article provides the options chain information for IQVIA Holdings Inc. (IQV) as of October 2, 2026. It shows real-time price data, noting an overnight session on the Blue Ocean ATS. The options data, delayed by 15 minutes, indicates no available calls or puts for May 21, 2027, across all strike prices.
UBS resumes coverage of IQVIA Holdings stock with USD 345.00 target
UBS has resumed coverage of IQVIA Holdings (ISIN US46266C1053) with a Buy rating and a price target of USD 345.00, citing improving bookings and the potential for AI-driven cost savings through IQVIA's data infrastructure. The valuation is based on expected operating leverage, with UBS projecting revenue growth of 4.00% to 5.00% and annual margin expansion through 2036. This renewed optimism follows IQVIA's strong second-quarter 2026 results, which surpassed analyst expectations for both earnings and revenue.
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)
The article reviews the Q2 performance of several drug development inputs & services stocks, highlighting West Pharmaceutical Services (WST) as a strong performer. It details the revenue and EPS beats for companies like Azenta (AZTA), IQVIA (IQV), Charles River Laboratories (CRL), and Repligen (RGEN), noting their individual strengths and market reactions to their earnings reports. The industry as a whole saw strong Q2 results, with revenues beating estimates and share prices performing well post-earnings.
IQVIA Holdings stock after-hours at EUR 238.10: minus 0.36 percent
IQVIA Holdings stock traded at EUR 238.10 after-hours on September 30, 2026, marking a 0.36 percent decrease from its prior close. The company is set to announce its third-quarter 2026 financial results on October 27, 2026, and recently announced plans for a $2.00 billion senior notes offering to refinance existing debt.
IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
IQVIA Holdings Inc. (NYSE:IQV) will announce its third-quarter 2026 financial results before market open on Tuesday, October 27, 2026. The management team will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. Interested parties can find the earnings release and webcast details on the IQVIA Investor Relations website.
Compass Therapeutics Inc. (CMPX) Stock Price Target & Forecast
This article provides an analysis of Compass Therapeutics Inc. (CMPX) stock, including analyst ratings and financial forecasts. Based on 15 analysts, the average price target for CMPX is $5.909, suggesting a significant upside. The article also details EPS forecasts, with FY2026Q3 projected at -0.127.
Medpace Holdings, Inc. (MEDP) Stock Price, News, Quote & History
This Yahoo Finance article provides a detailed overview of Medpace Holdings, Inc. (MEDP), including its stock price, historical performance, key financial metrics, and analyst ratings. It highlights the company's role as a clinical research organization offering drug and medical device development services globally. The article also presents performance comparisons against the S&P 500 and recent earnings trends.
IQVIA Holdings Q3FY26 Results: Earnings call scheduled for Oct 27
IQVIA Holdings Inc. (NYSE: IQV) will announce its third-quarter 2026 financial results before market open on October 27, 2026. A conference call and webcast for investors and analysts will be held at 9:00 am Eastern Time on the same day. Details for accessing the earnings release, financial information, and webcast replay will be available on the company's Investor Relations website.
IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
IQVIA Holdings Inc. (NYSE: IQV) will release its third-quarter 2026 financial results before the market opens on Tuesday, October 27, 2026. Following the release, the management team will host a conference call and webcast at 9:00 a.m. Eastern Time. Interested parties can find the earnings release and registration details on the IQVIA Investor Relations website.
IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
IQVIA Holdings Inc. (NYSE: IQV) will announce its third-quarter 2026 financial results before the market opens on Tuesday, October 27, 2026. The company's management team will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. Interested parties can access the earnings release and webcast details on the IQVIA Investor Relations website.
Medpace Holdings, Inc. (MEDP) latest stock news and headlines
This article provides a compilation of recent news and headlines regarding Medpace Holdings, Inc. (MEDP), showcasing its stock performance and various analyst opinions. It highlights MEDP's recent market outperformance and upcoming financial results announcement, while also featuring comparisons with other stocks and discussions on its valuation.
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and IQVIA Holdings (IQV)
Two analysts have offered bullish sentiments on healthcare companies Xencor (XNCR) and IQVIA Holdings (IQV). Truist Financial analyst Gregory Renza reiterated a Buy rating on Xencor with a $29.00 price target, while Truist Financial analyst Jailendra Singh reiterated a Buy rating on IQVIA Holdings with a $329.00 price target. Both companies have a "Strong Buy" analyst consensus, with Xencor having an average price target of $32.20 and IQVIA Holdings at $277.64.
IQVIA Holdings stock trades at EUR 239.40 with plus 0.02 percent
IQVIA Holdings stock saw a slight increase of 0.02 percent, trading at EUR 239.40 on September 29, 2026. The company reported Q2 revenue of USD 4.37 billion, an 8.7 percent year-over-year increase, with EPS exceeding consensus estimates. Analysts have raised their price targets for IQVIA, and the next earnings report is scheduled for October 27, 2026.
RBC Raises Price Target on IQVIA Holdings to $319 From $247, Keeps Outperform Rating
RBC Capital Markets has increased its price target for IQVIA Holdings (IQV) to $319 from $247, while maintaining an "Outperform" rating on the stock. This adjustment reflects a positive outlook from the analyst firm on the company's future performance. Other analysts have also recently adjusted their price targets for IQVIA, generally upward.
Devon Energy (NYSE:DVN) Stock Unloaded by Rep. Kevin Hern
Rep. Kevin Hern sold between $100,001 and $250,000 worth of Devon Energy stock from his family foundation account on August 31, 2026, alongside other recent sales in various companies. Despite this, Devon Energy reported strong quarterly results exceeding analyst expectations, with revenue up 73.1% year-over-year and a declared quarterly dividend of $0.32 per share. Institutional investors like BlackRock and State Street have increased their holdings, and analysts generally maintain a "Moderate Buy" rating with an average price target of $59.72.
Rep. Kevin Hern Sells Shares of Devon Energy Corporation (NYSE:DVN)
Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Devon Energy Corporation (NYSE: DVN) worth $15,001–$50,000 from his traditional IRA on August 31st, along with several other stock sales. Devon Energy reported strong quarterly earnings, exceeding analyst estimates, with revenue up 73.1% year over year, and declared a $0.32 quarterly dividend. Despite insider selling by an EVP and BP abandoning a potential asset acquisition, analysts maintain a "Moderate Buy" consensus for DVN.
IQVIA Holdings stock trades near its yearly high after HSBC target rise
IQVIA Holdings (IQV) stock is trading near its 52-week high after HSBC raised its price target to USD 300.00 from USD 280.00. The company's latest quarterly revenue of USD 4.37 billion exceeded expectations, and its earnings per share also beat consensus estimates. Despite trading above the average analyst target, the stock remains below HSBC's higher objective, with fiscal 2026 EPS guidance set at USD 12.80 to USD 13.00.
IQVIA stock at USD 270.37 on September 25, 2026, down 1.69 percent
IQVIA's stock was at USD 270.37 on September 25, 2026, marking a 1.69 percent decrease from the previous session. This news follows the company's announcement of a USD 2 billion senior-notes offering. The proceeds from this offering are intended for redeeming existing senior notes, repaying revolving credit facility borrowings, and covering associated fees.
Charles River Laboratories International, Inc. (CRL) Latest Stock News & Headlines - Yahoo Finance
This Yahoo Finance page provides the latest news and headlines for Charles River Laboratories International, Inc. (CRL), including articles on its stock performance, market forecasts for contract research organization and drug safety services, and the company's strategic vision. It also displays real-time stock quotes, recent performance data, and related news from various financial sources.
IQVIA Holdings stock heads into the open after closing at USD 268.05
IQVIA Holdings stock closed at USD 268.05 on the NYSE on September 24, 2026, and is heading into today's session. The company recently completed a $2 billion senior notes issuance, with proceeds intended to redeem existing notes, repay credit facilities, and cover related expenses. The stock's twelve-month range was between USD 154.50 and USD 277.40, with its closing price just below the high.
IQVIA Holdings Inc. stock outperforms competitors on strong trading day
IQVIA Holdings Inc. (IQV) saw its stock rise 2.67% to $275.02 on Thursday, outperforming the broader market which experienced a rough trading session. The S&P 500 Index fell 0.02% and the Dow Jones Industrial Average fell 0.31%. IQVIA Holdings Inc. closed just 0.86% below its 52-week high.
How AI Is Helping Match Patients to Clinical Trials Faster
This article discusses how AI is transforming clinical trial recruitment by streamlining patient identification, improving study design, and extracting insights from vast datasets. Pfizer's Vice President, Melinda Rottas, emphasizes that AI aids researchers in working more efficiently, reducing the time it takes to find eligible participants for trials, especially for conditions like oncology or rare diseases. The technology does not replace human decision-making but rather enhances researchers' ability to connect patients with suitable clinical trial opportunities, ultimately aiming to accelerate the development of life-changing treatments and expand access to underrepresented populations.
Iqvia completes $2 billion senior notes offering due 2034
IQVIA Holdings Inc. (NYSE:IQV) has completed a $2 billion offering of 6.375% senior notes due 2034, issued by its subsidiary IQVIA Inc. The proceeds will be used to redeem existing 5.000% notes due 2026, repay part of its revolving credit facility, and cover transaction expenses. This move comes as the company manages a total debt of $16.3 billion and follows strong Q2 adjusted earnings and revenue exceeding expectations, with analysts expressing optimism about its future.
IQVIA Holdings (IQV) Completes $2 Billion Senior Notes Offering to Refinance Debt
IQVIA Holdings Inc. (IQV) announced its wholly-owned subsidiary, IQVIA Inc., completed a $2 billion offering of 6.375% senior notes due 2034. The net proceeds will be used to redeem outstanding 5.000% senior notes due 2026, repay a portion of its revolving credit facility, and cover offering expenses. This refinancing extends IQVIA's debt maturity profile, though at a higher interest rate reflecting current market conditions.
Form 8K IQVIA Holdings Inc For: 23 September By Investing.com
This article reports that IQVIA Holdings Inc. filed a Form 8K on September 23. The article is a brief notification of this filing and includes stock market data for various indices, commodities, and shares, as well as trending stocks and popular news articles from Investing.com. It highlights IQVIA's stock performance (-0.83%) alongside other market movements.
Form 8K IQVIA Holdings Inc For: 23 September By Investing.com
This article reports on the filing of a Form 8K by IQVIA Holdings Inc. on September 23. The filing is a standard regulatory disclosure, indicating a significant event that shareholders should be aware of. The article itself serves as a brief announcement rather than providing detailed information about the content of the 8K form.
Form 8K IQVIA Holdings Inc For: 23 September By Investing.com
This article announces the filing of a Form 8K by IQVIA Holdings Inc. on September 23, 2026. It is a brief, news-style piece published by Investing.com, likely indicating a regulatory filing has been made. The article provides the company's stock symbol and a slight percentage change.
IQVIA Raises $2.0 Billion in 6.375% Senior Notes Due 2034 to Refinance Debt
IQVIA (IQV) has issued $2.0 billion in 6.375% senior unsecured notes due 2034 to refinance existing debt. The proceeds will be used to redeem 5.000% 2026 notes, reduce borrowings under its revolving credit facility, and cover associated fees. Interest payments for these new notes will be semi-annual, commencing March 15, 2027.
IQVIA Holdings stock closes at USD 271.10 near its yearly high
IQVIA Holdings stock closed at USD 271.10 on September 22, 2026, which is only USD 2.78 below its 52-week high of USD 273.88. The company's market capitalization reached USD 44.62 billion, with a P/E ratio of 33.66 and a PEG ratio of 2.28. Trading volume was notably subdued during the session, at 200,371 shares, significantly below the average volume.
iqvia holdings inc. Earnings dates
This article provides a list of past earnings dates for IQVIA Holdings Inc. (IQV), including reported EPS and revenue figures. It also features a news section with recent updates and earnings call information for IQVIA, along with a "Global Economics Weekly Update" video and other editor's picks.
IQVIA Holdings stock heads into the open after reaching USD 271.10
IQVIA Holdings (NYSE: IQV) stock closed at USD 271.10 on the NYSE on September 22, 2026, marking a USD 1.22 rise during the session. This occurred as the Nasdaq Composite gained 0.45 percent. The stock's closing price was USD 2.78 below its 52-week high, and a hedge fund reportedly reduced its holding in the company during the second quarter.
IQVIA Holdings, Inc. (IQV) Stock Analysis: Exploring Growth Potential With A 4.33% Upside
IQVIA Holdings, Inc. (IQV), a major player in healthcare diagnostics and research with a $43.85 billion market cap, shows a potential upside of 4.33%. Despite minimal recent stock fluctuation, its 8.70% revenue growth and 22.82% return on equity highlight strong financial health, supported by over $2.14 billion in free cash flow. Analyst sentiment is overwhelmingly positive, with an average target price of $277.94, suggesting continued momentum for growth-focused investors in the evolving healthcare landscape.
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
IQVIA (IQV) stock has gained 60.1% in the past six months, outperforming its industry and the S&P 500. This growth is attributed to accelerating organic growth, strong R&DS bookings and backlog, and rapid AI adoption, which strengthens its competitive position. The company's R&DS business saw 7% organic growth, while the commercial side grew 5% year-over-year, and AI adoption has expanded significantly with 294 AI agents deployed across 90 use cases.
Phillips 66 price soars - Forecast today - 16-09-2026
Phillips 66 (PSX) stock has resumed its advance, maintaining a primary medium-term uptrend and trading above its 50-day Simple Moving Average. The outlook remains bullish for upcoming trading sessions, provided support at $245.00 holds, with a target resistance level of $289.00. The stock has also worked off overbought conditions in momentum indicators, allowing for further gains.
IQVIA Holdings stock hits 52-week high at 271.82 USD
IQVIA Holdings Inc. (IQV) stock reached a new 52-week high of $271.82, reflecting a 45.17% increase over the past year and a 61% return in the last six months. With a market capitalization of $44.6 billion, the company demonstrates strong performance in the Life Sciences Tools & Services industry. Despite trading above its Fair Value, investor confidence remains high, bolstered by recent earnings and revenue beats, a $2 billion senior notes offering, and upward revisions of price targets by analysts.
IQVIA Holdings stock hits 52-week high at 271.82 USD By Investing.com
IQVIA Holdings Inc. (IQV) stock reached a new 52-week high of $271.82, reflecting a 45.17% increase over the past year and a 61% return in the last six months. This surge in price, despite the stock trading above its Fair Value, is backed by strong financial results, including exceeding Q2 adjusted earnings and revenue expectations, and positive analyst revisions and price target increases from firms like Stifel and Truist Securities. The company's market capitalization stands at $44.6 billion, highlighting its prominent position in the Life Sciences Tools & Services industry.
IQVIA Holdings stock hits 52-week high at 271.82 USD By Investing.com
IQVIA Holdings Inc. stock reached a 52-week high of $271.82, reflecting a 45.17% increase over the past year and a 61% return in the last six months. The company, with a market capitalization of $44.6 billion, is performing strongly in the Life Sciences Tools & Services industry, although InvestingPro analysis indicates it trades above its Fair Value. Analysts have responded positively to IQVIA's recent financial results, including exceeding Q2 earnings and revenue expectations and a $2 billion senior notes offering, leading to increased price targets from Stifel and Truist Securities.
The Trade Desk, Inc. Expands Integrations with Veeva Systems Inc. and Iqvia Holdings Inc. for Healthcare Measurement and Optimization for Pharma Advertisers
The Trade Desk, Inc. has expanded its integrations with healthcare analytics providers Veeva Systems Inc. and IQVIA Holdings Inc. These enhancements will provide pharmaceutical advertisers with more detailed insights into campaign performance, enabling better media optimization and decision-making. The goal is to bridge the gap between insight and action, allowing advertisers to apply learnings and make real-time adjustments to maximize campaign outcomes and audience targeting.
IQVIA Holdings stock hits 52-week high at 271.82 USD By Investing.com
IQVIA Holdings Inc. (IQV) stock has reached a new 52-week high of 271.82 USD, marking a significant increase of 45.17% over the past year and 61% in the last six months. The company, with a market capitalization of $44.6 billion, recently reported second-quarter adjusted earnings and revenue that exceeded analyst expectations, and announced a $2 billion senior notes offering. Analysts from Stifel and Truist Securities have raised their price targets for IQVIA, citing improving market conditions and the company's AI strategy.
A Strong Rebound Case of IQVIA Holdings (IQV)
Broyhill Asset Management's Q2 2026 investor letter highlighted IQVIA Holdings Inc. (IQV) as a strong rebound case, with the stock gaining 14% after being a detractor in the previous quarter. The firm noted improved results and request-for-proposal flow for IQV, attributing its recent gains to these factors. Despite trimming its position in IQV, Broyhill maintains its investment philosophy focused on capital protection and acknowledges the potential for IQV as biopharma outsourcing increases.
CCF deal adds $589M revenue and $1.50B debt, Katapult (KPLT) says
Katapult Holdings, Inc. (KPLT) has filed an amendment detailing the financial statements of acquired companies CCF Holdings LLC and Aaron's Intermediate Holdco, Inc., following their business combination. For the first half of 2026, CCF Holdings reported $589.8 million in net revenues and $79.3 million in net income, alongside significant debt of $1.50 billion. The amendment provides investors with pro forma data to assess Katapult's combined financial profile.
IQVIA Holdings Announces $2 Billion Senior Notes Offering
IQVIA Holdings announced a private offering of $2 billion in senior notes due 2034, with an interest rate of 6.375%. The proceeds will be used to redeem existing senior notes, repay part of its revolving credit facility, and cover transaction expenses, optimizing the company's capital structure. TipRanks' AI Analyst rated IQVIA Holdings as "Outperform" due to strong earnings momentum and a clear technical uptrend, despite concerns about leverage and valuation.
Form 8K IQVIA Holdings Inc For: 10 September By Investing.com
This article reports on the filing of a Form 8K by IQVIA Holdings Inc. on September 10. The brief entry provides the company name and filing date, without offering further details on the content of the Form 8K. It also mentions IQVIA's stock performance.
Form 8K IQVIA Holdings Inc For: 10 September By Investing.com
This article reports that IQVIA Holdings Inc. filed a Form 8K on September 10. The filing, available on Investing.com, indicates a significant event for the company, aligning with regulatory disclosure requirements. The article itself is brief, primarily serving as an announcement of the filing rather than an analysis of its content.
How New Instrument Launches At Thermo Fisher Scientific Stock Have Changed Its Investment Story
Thermo Fisher Scientific recently launched two new instruments, the Multiskan Ease Absorbance Microplate Reader and the EMPAD G2 detector, which expand its offerings in biological assays and advanced materials research. While these product introductions are incremental rather than transformational, they reinforce the company's commitment to refreshing its portfolio and aligning with evolving customer expectations and sustainability programs. Analysts project Thermo Fisher Scientific's revenue to reach US$54.8 billion and earnings to hit US$9.9 billion by 2029, suggesting a 5% upside to its current share price, with an implied P/E multiple compression baked into future forecasts.
